

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Equality impact assessment

IPG424 Focal therapy using high-intensity focused ultrasound for localised prostate cancer

The impact on equality has been assessed during guidance development according to the principles of the NICE Equality scheme.

Scoping

1. Have any potential equality issues been identified during the scoping process (development of the scope or discussion at the Committee meeting), and, if so, what are they?

Prostate cancer is the most common cancer in men and now makes up approximately 25% of the new diagnoses of malignant cancer in men in England and Wales.

There is a higher incidence of prostate cancer in the less socio-economically deprived areas, which may reflect higher uptake of prostate specific antigen (PSA) testing among affluent men (cancer registries of England and Wales).

In the UK, black Caribbean and black African men have approximately two to three times the risk of being diagnosed or dying from prostate cancer than white men, while Asian men generally have a lower risk than the national average.

Men with prostate cancer are covered by equalities legislation.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? If there are exclusions listed in the scope (for example, populations, treatments or settings), are these justified?

This was not thought to have an impact on the assessment of the procedure. No exclusions were applied.

3. Has any change to the scope (such as additional issues raised during the Committee meeting) been agreed to highlight potential equality issues?

No

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No specific data relating to the potential issues mentioned earlier was identified in the literature presented in the overview.

2. Have any other potential equality issues been raised in the overview, specialist adviser questionnaires or patient commentary, and, if so, how has the Committee addressed these?

No

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group?

No

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligation to promote equality?

Not applicable

6.	Have the Committee's considerations of equality issues been described in the consultation document, and, if so, where?
No	

Final interventional procedures document

1.	Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?
No	

2.	If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group?
Not applicable	

3.	If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?
Not applicable	

4.	Have the Committee's considerations of equality issues been described in the final interventional procedures document, and, if so, where?
No	

Approved by Centre or Programme Director: Approved

Date: 30.01.12